Landscape Capital Management L.L.C. Lowers Holdings in Johnson & Johnson (NYSE:JNJ)

Landscape Capital Management L.L.C. reduced its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 6.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,027 shares of the company’s stock after selling 565 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Johnson & Johnson were worth $1,250,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Rather & Kittrell Inc. increased its position in shares of Johnson & Johnson by 2.0% in the second quarter. Rather & Kittrell Inc. now owns 2,909 shares of the company’s stock valued at $481,000 after buying an additional 58 shares in the last quarter. Capital Square LLC increased its holdings in Johnson & Johnson by 1.4% in the 2nd quarter. Capital Square LLC now owns 4,245 shares of the company’s stock worth $703,000 after acquiring an additional 58 shares in the last quarter. Wagner Wealth Management LLC raised its position in Johnson & Johnson by 1.3% during the second quarter. Wagner Wealth Management LLC now owns 4,543 shares of the company’s stock worth $752,000 after acquiring an additional 59 shares during the period. Chesapeake Wealth Management lifted its holdings in Johnson & Johnson by 0.7% during the second quarter. Chesapeake Wealth Management now owns 9,196 shares of the company’s stock valued at $1,522,000 after purchasing an additional 60 shares in the last quarter. Finally, RPG Investment Advisory LLC increased its stake in shares of Johnson & Johnson by 1.2% during the second quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock worth $807,000 after purchasing an additional 60 shares in the last quarter. 68.40% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Raymond James boosted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $167.00 to $180.00 in a report on Friday, December 1st. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $176.14.

Check Out Our Latest Analysis on JNJ

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $157.87 on Tuesday. The firm has a market cap of $380.04 billion, a PE ratio of 11.43, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The business’s fifty day simple moving average is $158.18 and its 200-day simple moving average is $158.62.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter in the prior year, the company posted $2.35 earnings per share. Johnson & Johnson’s revenue for the quarter was down 9.7% compared to the same quarter last year. Equities analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be given a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s payout ratio is 34.47%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.